Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5694/j.1326-5377.2003.tb05187.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthetic data as external control arms in scarce single-arm clinical trials.
PLOS Digit Health
January 2025
Cancer Registry of Norway, Norwegian Institute of Public health, Ullernchausseen 64, 0379 Oslo, Norway.
An external control arm based on health registry data can serve as an alternative comparator in single-arm drug development studies that lack a benchmark for comparison to the experimental treatment. However, accessing such observational healthcare data involves a lengthy and intricate application process, delaying drug approval studies and access to novel treatments. Clinical trials typically comprise only a few hundred patients usually with high-cardinality features, which makes individual data instances more exposed to re-identification attacks.
View Article and Find Full Text PDFRegulation and Compliance in Telemedicine: Viewpoint.
J Med Internet Res
January 2025
Doxy.me Research, Doxy.me, Inc, Charleston, SC, United States.
The US COVID-19 Public Health Emergency ended on May 11, 2023. Lawmakers and regulators extended some flexibilities while they deliberate effective long-term telemedicine policy. Here, we discuss critical challenges in telemedicine compliance and regulation grounded in scholarly literature and current events.
View Article and Find Full Text PDFInsights into youth nutritional status in Serbia: assessing prevalence and trend in the context of social determinants.
BMC Public Health
January 2025
College of Sports and Health, Toše Jovanovića 11, Belgrade, 11000, Serbia.
Background: The study aimed to assess the prevalence and distribution of different levels of nutritional status among young people, to examine its association with social determinants of health, and to analyse its trend over time.
Method: The research was a secondary analysis of the data from four national health surveys of the Serbian population. The research sample included 11,243 respondents, aged 15 to 29, both genders.
The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment.
BMC Complement Med Ther
January 2025
Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Background: Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer's disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuroprotective and anti-inflammatory properties. In CBD research, PE is underutilized too.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!